{
  "docId": "019de075-c47e-7083-a54f-f1c9e61a9c49",
  "docSlug": "c4e46035e95877be205ecc394d7dd292",
  "documentTitle": "OmniAb | Results Presentation Deck | 20 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 20,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c47e-7083-a54f-f1c9e61a9c49/9",
  "deckHref": "/decks/019de075-c47e-7083-a54f-f1c9e61a9c49",
  "deckJsonHref": "/decks/019de075-c47e-7083-a54f-f1c9e61a9c49.json",
  "deckAnchorHref": "/decks/019de075-c47e-7083-a54f-f1c9e61a9c49#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.04,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Number of Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c7f3561-c47c-484e-a53b-8ff653968ce4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.3,
        "y": 0.25
      },
      "kind": "list",
      "text": "2 new programs entered the clinic in Q2; IMVT-1402 (Immunovant): Next-generation FcRn antagonist; GLS-012 (Gloria): anti-LAG-3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50eda05c-2725-4be2-9064-98924920b60c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.3,
        "y": 0.45
      },
      "kind": "list",
      "text": "3 new programs have entered the clinic so far in the first half of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a308c542-e081-4542-bef9-c4432c40a12f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.3,
        "y": 0.55
      },
      "kind": "list",
      "text": "Based on dialog with our partners, we see potential for 1-2 additional new entries into clinical development for novel OmniAb-derived antibodies in the second half of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b08663cd-cd67-4382-bd16-367d8788ba10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "list",
      "text": "Partner progression also continuing to show the flexibility of our platform, with an increasing number of formats and modalities in clinical or preclinical development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6e10bd0-6559-42f3-8046-7f09dd40c973",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "TWO NEW CLINICAL ENTRANTS IN Q2 2023",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "974f208d-44c3-4da3-9c66-c67d24ea01a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9e40543-c412-45b1-8867-7be07e0ea76b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "1a7555b1-cab3-4fdd-b9d6-a4d1379e802b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "KPIs, partner updates, and financial results slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}